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Abstract
Background. The objective of the study was to investigate the utility of deprescribing paracetamol in 
cancer patients receiving opioids for moderate-to-severe pain.
Material and methods. Patients with well-controlled cancer pain (average pain intensity ≤ 4/10), who 
were receiving regular paracetamol and an opioid for moderate-to-severe pain, completed the Brief Pain 
Inventory — Short Form at baseline and at seven days post discontinuation of the paracetamol (or sooner 
if restarting the paracetamol). The study employed a Simon optimal two-stage design with the aim of 
reducing the number of subjects exposed to a “futile” intervention.
Results. Forty-four patients were enrolled, and 40 patients completed the study. Eighteen (45%) patients 
restarted the paracetamol, although another four patients reported a worsening of pain control and/or 
an increase in the use of rescue medication. The only factor associated with restarting paracetamol was 
the pathophysiology of the pain, with patients with mixed pain more likely to restart paracetamol than 
patients with nociceptive pain (P = 0.013).
Conclusions. On the basis of these results we would recommend a trial of discontinuing paracetamol in all 
patients receiving opioids for moderate-to-severe pain, who are deemed to be adequately pain controlled. 
The patients can be reassured that there is approximately a one in two chance of not needing to restart 
the paracetamol, and that if they do need to start the paracetamol, pain control can be re-gained within 
a very short period of time.
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Introduction
Paracetamol (acetaminophen) is a non-opioid, 
which is recommended for use at step I (i.e. non-opio-
id +/– adjuvant), step II (i.e. opioid for mild-to-mode-
rate pain + non-opioid +/– adjuvant), and step III (i.e. 
opioid for moderate-to-severe pain +/– non-opioid 
+/– adjuvant) of the World Health Organization three 
step analgesic ladder [1]. It is undoubtedly an effective 
analgesic, and it has an unrivalled adverse effect pro-
file [2]. Nevertheless, a recent systematic review of the 
literature concluded that “there is insufficient evidence 
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and d) alteration in oncology therapy in preceding 
four weeks. 
The patients were given a standard information 
sheet, time to consider the study, opportunity to 
discuss the study (with researchers / others), and 
asked to provide a formal written consent before the 
enrolment. On the first day of the study the patients 
were assessed by a researcher and asked to complete 
the Brief Pain Inventory — Short Form (BPI — SF) [10], 
and the Leeds Assessment of Neuropathic Symptoms 
and Signs (LANSS) [11]; the researchers used the data 
from these tools and other information in the electro-
nic patient record to determine the aetiology of the 
pain (i.e. cancer-related, cancer treatment-related, 
other cause), and the pathophysiology of the pain (i.e. 
nociceptive, neuropathic, mixed). The patients were 
then asked to discontinue taking paracetamol, and 
advised to contact the research team should there be 
any deterioration in their pain control. 
The patients were reviewed after 48 hours and 
asked to complete the pain scales on the BPI — SF; 
the reviews were done either in person or on the te-
lephone. On the last day of the study (seventh day), 
the patients were again assessed by a researcher and 
asked to complete the Brief Pain Inventory — Short 
Form (BPI — SF). The patients were also asked the 
questions: “Since stopping your paracetamol do you 
feel your pain control has got worse?” (option: yes 
or no); “Since stopping your paracetamol do you feel 
you have had to use more ‘breakthrough’ / ‘rescue’ 
painkillers?”(option: yes or no); “Do you want to re-
start your paracetamol?” (option: yes or no).
If a patient wanted to restart paracetamol before 
the end of the study (and contacted the research 
team), he was asked to complete the pain scales on 
the BPI — SF before restarting the paracetamol, and 
48 hours after starting the paracetamol; the reviews 
were again done in person or on the telephone.
The study employed a Simon optimal two-stage 
design [12], which is frequently used in phase II on-
cology trials (with the aim of reducing the number 
of subjects exposed to a “futile” intervention). The 
sample sizes were based on a p0 (pre-specified null 
hypothesis response probability) = 0.5, a p1 (mi-
nimum desired response probability) = 0.7, an al-
pha = 0.05 and a power = 80%. Initially 15 patients 
were recruited, with a plan to stop the study if > 6 pa-
tients restarted the paracetamol; subsequently, a fur-
ther 28 patients were recruited, with a plan to stop 
the study if  > 16 patients restarted the paracetamol. 
[The plan was to recruit to a maximum of 80 patients, 
which would provide a 95% confidence interval of 
+/– 11% on the estimate of the proportion of patients 
restarting paracetamol].
to support the use of paracetamol in combination 
with Step III opioids” in patients with cancer pain [3].
Most of the randomised controlled studies in 
the aforementioned systematic review investigated 
the effect of adding paracetamol to an analgesic 
regimen containing an opioid for moderate-to-seve-
re pain [4–7]. However, Axelsson & Christensen [8] 
investigated the effect of removing paracetamol from 
such an analgesic regimen in 30 patients with well 
controlled pain (i.e. “average” pain intensity < 4/10); 
they reported no difference in pain intensity between 
the treatment period with paracetamol and the tre-
atment period with placebo. It should be noted that 
42 patients entered this study, but only 30 patients 
completed this study.
Subsequently, Axelsson et al. [9] reported an un-
controlled study of the effect of removing paracetamol 
from an analgesic regimen containing an opioid for 
moderate-to-severe pain; they reported that 68% of pa-
tients reported no difference in pain after discontinuing 
the paracetamol (with 6% of patients reporting less 
pain), and that 53% did not want to take paracetamol 
at the end of the study. The patients in this study were 
again well pain controlled (i.e. pain intensity < 4/10), 
and also on a stable analgesic regimen (i.e. no change 
in opioid dose in the past week). It should be noted, 
that only 34 patients completed this study.
The aim of the current study was to obtain fur-
ther data about the utility of paracetamol in patients 
receiving opioids for moderate-to-severe pain that 
are deemed to be well pain controlled (and specifi-
cally whether or not paracetamol can reasonably be 
omitted in this situation). Indeed, Axelsson et al. [9] 
highlighted the need for additional data to support 
clinical decision making.
Material and methods
The study was conducted at the Royal Marsden 
Hospital NHS Foundation Trust in the United Kingdom. 
The study was approved by the Royal Marsden Hospi-
tal Committee for Clinical Research, the local Research 
Ethics Committee, and the Medicines and Healthcare 
Products Regulatory Agency (MHRA). 
The subjects were recruited from both inpatient 
wards and outpatient clinics. The inclusion criteria 
for the study were: a) age > 18 years; b) diagnosis of 
cancer; c) regular opioid for moderate-to-severe pain 
(“strong opioid”) for preceding seven days; d) regular 
paracetamol for preceding seven days (i.e. ≥ 2 g/day); 
and e) average pain intensity ≤ 4/10 for preceding 
24 hours. The exclusion criteria for the study were: 
a) estimated prognosis < 2 weeks; b) cognitive im-
pairment; c) radiotherapy in preceding four weeks; 
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The data were analysed using SPSS (Version 19) soft- 
ware. Binary logistic regression was used to determine 
the relationship between restarting paracetamol and 
demographics, aetiology of pain, pathophysiology of 
pain, baseline pain intensity scores, and baseline dose 
of regular opioid (i.e. morphine equivalent daily dose).
Results
Forty-four patients were enrolled into the study, 
and 40 patients completed the study (Fig. 1). The 
median age of the subjects was 63 years (range 31– 
–80 years). The other characteristics of the subjects are 
shown in Table 1. At baseline, the median “average” 
pain intensity was 2 (range 0–4), the median “least” 
pain was 0 (range 0–3), and the median “worst” pain 
was 3 (range 0–10) in the whole group.
Eighteen (45%; 95% confidence interval: 30–60%) 
patients restarted the paracetamol; 11 (61%) restarted 
before day seven (end of the study), whilst seven (39%) 
restarted on day seven. For the patients that restarted 
before the end of the study, the median time to restar-
ting was three days (range one to six days). In eight of 
these patients, pain scores were obtained on the day 
of restarting the paracetamol and 48 hours later; seven 
of these eight patients reported improvement in pain 
scores after restarting the paracetamol (Tab. 2).
Twenty-two (55%) patients did not restart the 
paracetamol, although two reported that their pain 
control had got worse, and three stated that they had 
used more rescue medication during the study period. 
[One of the patients who reported that their pain had 
got worse also stated that he had used more rescue 
medication]. In total, therefore, 18 (45%) patients 
reported no negative effect on pain control following 
discontinuation of the paracetamol. On dayseven, the 
median “average” pain intensity was 1 (range 0–6), 
Table 1. Patient characteristics
Characteristic Number patients
(n = 44)
Gender
Male
Female
 
25 (57%)
19 (43%)
Cancer diagnosis 
Breast 
Gastrointestinal
Gynaecological
Haematological
Head & neck
Lung
Sarcoma
Urological
 
5 (11.5%)
12 (27.5%)
3 (7%)
1 (2%)
1 (2%)
4 (9%)
1 (2%)
17 (39%)
Aetiology pain
Cancer-related
Cancer treatment-related
Unknown
 
42 (96%)
1 (2%)
1 (2%)
Pathophysiology pain
Nociceptive
 — Somatic
 — Visceral
Neuropathic
Mixed
 
39 (88.5%)
–27
–12
0 (0%)
5 (11.5%)
Figure 1. Study flow chart
44 patients randomised
to the study
40 patients completed
the study
22 patients did not
restart paracetamol
18 patients did restart paracetamol
— 11 prior to end of study
— 7 at end of study
3 withdrawals (protocol violations) 
1 death (progressive disease)
the median “least” pain was 0 (range 0–5), and the 
median “worst” pain was 2 (range 0–9) in this group.
Univariate analysis of the potential factors associa-
ted with restarting paracetamol demonstrated a signi-
ficant difference in terms of the pathophysiology of the 
pain, with all five (out of five) patients with mixed pain 
restarting, compared with 13 (out of 35) patients with 
nociceptive pain [Fisher’s Exact Test: P = 0.013]. How- 
ever, univariate analysis found no relationship between 
restarting paracetamol and demographics, aetiology of 
pain, the baseline pain intensity scores, or the baseline 
dose of regular opioid (i.e. morphine equivalent daily 
dose / MEDD). The median MEDD for the group that 
restarted paracetamol was 120 mg (range 40–720 mg), 
whilst the median MEDD for the group that did not 
restart paracetamol was 95 mg (range 40–600 mg).
Discussion
Paracetamol is commonly used to treat cancer 
pain [13], and is recommended for use at all levels of 
the World Health Organization three step analgesic 
ladder [1]. Many patients start paracetamol at step 
I or II, and continue with paracetamol at step III (even 
though there is often little evidence of a clinically 
significant analgesic effect). However, paracetamol’s 
mechanism of action is somewhat different from 
that of opioids (and non-steroidal anti-inflammatory 
drugs) [14], which means that it can have an additive 
effect (and, potentially, an opioid-sparing effect) [15].
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The results of this study confirm that paracetamol 
does have a role in the management of cancer pain 
in patients receiving opioids for moderate-to-severe 
pain, but that many (~ 50%) of these patients could 
stop taking paracetamol without negative effects on 
their pain control. Our results are similar to those of 
Axelsson et al. [9], who reported that 53% of their 
patients wanted to stop taking regular paracetamol. 
Moreover, Axelsson et al. also found no association 
between restarting paracetamol and demographics, 
aetiology of pain, or the baseline dose of regu-
lar opioid.
Paracetamol has few adverse effects or drug inter- 
actions. Thus, the major downside of taking parace-
tamol is the tablet burden, i.e. 8 tablets per day if the 
patient is taking 1 g four times a day (utilising 500 mg 
tablets) [16]. Discontinuing paracetamol and reducing 
the patients tablet burden may improve adherence 
with other medication (and so improvement in other 
symptoms). Furthermore, discontinuing paracetamol 
will also result in significant financial savings for the 
patients and the healthcare service (even though the 
drug is relatively inexpensive).
On the basis of these results (and those of Axelsson 
et al. [9]), we would recommend a trial of disconti-
nuing paracetamol in all patients receiving opioids 
for moderate-to-severe pain who are adequately pain 
controlled. The patients can be assured that there is 
approximately a one in two chance of not needing 
to restart the paracetamol, and that if they do need 
to start the paracetamol, the pain control can be 
re-gained within a very short period of time (i.e. less 
than 48 hours).
However, we would not recommend routinely dis-
continuing paracetamol in patients receiving opioids 
for moderate-to-severe pain who are inadequately 
pain controlled (unless there is an issue around tablet 
burden / adherence). Moreover, we would suggest that 
patients receiving opioids for moderate-to-severe pain 
who are inadequately pain controlled, and who are 
not receiving regular paracetamol, should be given 
a therapeutic trial of this unique non-opioid analgesic.
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